-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK's Nelkarmi Gets US FDA Nod for Lung Cancer Treatment

MT Newswires·11/17/2026 23:28:24
Listen to the news
11:28 PM EST, 11/17/2026 (MT Newswires) -- GSK (GSK.L) received accelerated approval from the US Food and Drug Administration for Nelkarmi as a treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase, or ALK, positive non-small cell lung cancer who have previously been treated in the unresectable locally advanced or metastatic setting. The approval, ahead of the original FDA target action date of Nov. 27, is based on the outcome of the phase I/II Alkove-1 trial, according to a Tuesday release. The UK-listed drugmaker recorded a confirmed overall response rate, or ORR, of 49% with a duration of response, or DOR, of six or more months in 76% of responders and 12 or more months in 52% of responders previously treated with alectinib as their only prior ALK tyrosine kinase inhibitor, or TKI. In patients with two or more previous ALK TKIs and chemotherapy, the ORR was 32%, with DOR of six or more months in 69% of responders and 12 or more months in 51% of responders.